Lupus Anticoagulant

other

Lupus anticoagulant promotes coronary thrombosis through tissue-factor and coagulation pathway activation.

Pathway placement

Cascade stepCoagulation & thrombus formation

Confidencehigh

RationaleProthrombotic autoantibody driving in vivo coagulation and coronary thrombosis.

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresIndeterminate

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+23.8

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossmag 1

3hypovolemia / dehydrationmag 1

4tachyarrhythmiamag 1

5hypoxemia / respiratory failuremag 2

6hypertensive emergencymag 1

7high-demand / peri-operative stressmag 1

Coverage: 7/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST)

Method / principle

Method depends on analyte chemistry

Reagent / substrate

Analyte-specific

Platform

Variable

Turnaround · availability

Research · Research

Antiphospholipid antibodies in young myocardial infarction patients.
Indian journal of biochemistry & biophysics · 2007 · PMID 18320848